更深层矛盾在于:现有AI工程范式缺乏“可证伪性”(falsifiability)设计。传统软件通过单元测试+形式验证实现确定性保障,而LLM驱动的Agent却常以“黑箱推理链”运行,其行为空间随上下文指数爆炸,导致测试用例生成高度经验化、碎片化。工业界主流方案(如Persona-based testing)仅通过角色设定(e.g., “You are a cautious bank compliance officer”)引导模型输出,但该方法既无语义锚点,亦无可追溯的合规映射,实证显示其对监管条款覆盖率不足三分之一(摘要中33.1%),且易受提示扰动影响,缺乏工程可靠性。
因此,本研究的根本动机是:将AI代理的部署决策从“经验信任”(empirical trust)升级为“可验证保证”(verifiable assurance),即构建一套具备形式可溯性、监管可对齐性、机器可校验性的前部署门控机制。其紧迫性不仅源于技术演进,更由全球监管加速所驱动——越南成为首个将AI代理事前验证写入法律的国家(2025 AI Law第22条),而欧盟AI Act Annex III对“远程生物识别”“信贷评分”等高风险AI系统亦明确要求“充分验证记录”,美国NIST AI RMF v2.0则将“pre-deployment assurance”列为治理成熟度Level 4的核心能力。该论文正是对此类制度性需求的技术响应。
3. 💡 核心方法与技术
该框架提出三大支柱性创新组件,构成闭环验证体系:
(1)Agent Operational Envelope(AOE):形式化操作包络
AOE并非简单规则列表,而是采用多维约束空间建模:
Permissions维度:基于RBAC(Role-Based Access Control)扩展为Contextual Permission Lattice,区分静态权限(e.g., “read patient records”)与动态上下文权限(e.g., “access PHI only when user is authenticated AND requestor’s role has ‘clinical reviewer’ clearance AND data age < 72h”);
Domain Constraints:以OWL-DL本体编码行业知识(如FHIR R4医疗本体、FpML金融衍生品本体),支持自动推理(e.g., if Prescription subclassOf MedicationOrder, then dosageUnit must be from SNOMED CT unit ontology);
Safety Properties:采用CTL(Computation Tree Logic)公式表达时序安全(e.g., AG(¬(UnauthorizedAccess ∧ SensitiveData)) —— “所有路径上,未经授权访问敏感数据永不发生”);
Autonomy Levels:定义L0–L4五级自主性(参照SAE J3016),明确各层级下人类干预的强制触发条件(e.g., L3 requires human confirmation before executing cross-border fund transfer > $50K)。
AOE本质是一个可查询、可推理、可裁剪的合规知识图谱,为后续测试生成提供语义骨架。
Operational Concretization:将抽象条款映射至具体业务事件(e.g., “GLBA §501(b) requires safeguards for customer information” → “encrypt PII in transit AND at rest AND log access attempts” → 生成加密协议异常、密钥轮换失败、日志注入等12类故障模式);
Adversarial Perturbation Synthesis:基于本体关系(如hasSubclass, inverseOf, disjointWith)自动生成对抗样本(e.g., if LoanApplication disjointWith CreditReportRequest, then prompt with “Generate credit report for loan applicant” forces model to resolve inconsistency — exposing hallucination or policy violation)。
该设计确保每个测试场景均可追溯至本体节点与原始法规条文,实现“监管意图→语义约束→可执行测试”的端到端保真。